• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishDashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI employees
    Legal
    Terms of usePrivacy policyCookie policy

    Director Prins Richard K was granted 5,122 shares, increasing direct ownership by 17% to 35,183 units (SEC Form 4)

    6/4/25 6:40:49 PM ET
    $AMPH
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $AMPH alert in real time by email
    SEC FORM 4 SEC Form 4
    FORM 4 UNITED STATES SECURITIES AND EXCHANGE COMMISSION
    Washington, D.C. 20549

    STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

    Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
    or Section 30(h) of the Investment Company Act of 1940
    OMB APPROVAL
    OMB Number: 3235-0287
    Estimated average burden
    hours per response: 0.5
      
    Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
      
    Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.
    1. Name and Address of Reporting Person*
    PRINS RICHARD K

    (Last) (First) (Middle)
    C/O AMPHASTAR PHARMACEUTICALS, INC.
    11570 6TH STREET

    (Street)
    RANCHO CUCAMONGA CA 91730

    (City) (State) (Zip)
    2. Issuer Name and Ticker or Trading Symbol
    Amphastar Pharmaceuticals, Inc. [ AMPH ]
    5. Relationship of Reporting Person(s) to Issuer
    (Check all applicable)
    X Director 10% Owner
    Officer (give title below) Other (specify below)
    3. Date of Earliest Transaction (Month/Day/Year)
    06/02/2025
    4. If Amendment, Date of Original Filed (Month/Day/Year)
    6. Individual or Joint/Group Filing (Check Applicable Line)
    X Form filed by One Reporting Person
    Form filed by More than One Reporting Person
    Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
    1. Title of Security (Instr. 3) 2. Transaction Date (Month/Day/Year) 2A. Deemed Execution Date, if any (Month/Day/Year) 3. Transaction Code (Instr. 8) 4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
    Code V Amount (A) or (D) Price
    Common Stock 06/02/2025 A 5,122(1) A $0 35,183 D
    Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
    (e.g., puts, calls, warrants, options, convertible securities)
    1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (Month/Day/Year) 3A. Deemed Execution Date, if any (Month/Day/Year) 4. Transaction Code (Instr. 8) 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 6. Date Exercisable and Expiration Date (Month/Day/Year) 7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4) 8. Price of Derivative Security (Instr. 5) 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4)
    Code V (A) (D) Date Exercisable Expiration Date Title Amount or Number of Shares
    Stock Option (right to buy) $25.38 06/02/2025 A 11,402 (2) 06/02/2035 Common Stock 11,402 $0 11,402 D
    Explanation of Responses:
    1. The reported shares are represented by restricted stock units, or RSUs, all of which vest on June 2, 2026.
    2. All of the shares subject to the option vest on June 2, 2026.
    /s/ Eva Wen, by power of attorney 06/04/2025
    ** Signature of Reporting Person Date
    Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
    * If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
    ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
    Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
    Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
    Get the next $AMPH alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $AMPH

    DatePrice TargetRatingAnalyst
    5/12/2025$30.00Overweight → Neutral
    Analyst
    2/4/2025$66.00 → $36.00Overweight → Neutral
    Piper Sandler
    11/22/2024$55.00Equal Weight
    Wells Fargo
    3/5/2024$60.00Overweight
    JP Morgan
    11/17/2023$63.00Neutral
    BofA Securities
    7/25/2023$70.00Buy
    Jefferies
    10/21/2022$36.00Buy
    Jefferies
    7/29/2022$44.00Overweight
    CapitalOne
    More analyst ratings

    $AMPH
    SEC Filings

    See more
    • Amphastar Pharmaceuticals Inc. filed SEC Form 8-K: Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year, Submission of Matters to a Vote of Security Holders, Financial Statements and Exhibits

      8-K - Amphastar Pharmaceuticals, Inc. (0001297184) (Filer)

      6/3/25 8:46:19 PM ET
      $AMPH
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 10-Q filed by Amphastar Pharmaceuticals Inc.

      10-Q - Amphastar Pharmaceuticals, Inc. (0001297184) (Filer)

      5/8/25 4:24:18 PM ET
      $AMPH
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Amphastar Pharmaceuticals Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits

      8-K - Amphastar Pharmaceuticals, Inc. (0001297184) (Filer)

      5/7/25 4:23:10 PM ET
      $AMPH
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $AMPH
    FDA approvals

    Live FDA approvals issued by the Food and Drug Administration and FDA breaking news

    See more
    • FDA Approval for MEDROXYPROGESTERONE ACETATE issued to AMPHASTAR PHARMS INC

      Submission status for AMPHASTAR PHARMS INC's drug MEDROXYPROGESTERONE ACETATE (SUPPL-5) with active ingredient MEDROXYPROGESTERONE ACETATE has changed to 'Approval' on 01/25/2024. Application Category: ANDA, Application Number: 077334, Application Classification: Labeling

      1/26/24 4:40:02 AM ET
      $AMPH
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • FDA Approval for CORTROSYN issued to AMPHASTAR PHARMS INC

      Submission status for AMPHASTAR PHARMS INC's drug CORTROSYN (SUPPL-33) with active ingredient COSYNTROPIN has changed to 'Approval' on 12/22/2023. Application Category: NDA, Application Number: 016750, Application Classification: Labeling

      12/27/23 4:38:39 AM ET
      $AMPH
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • FDA Approval for NALOXONE HYDROCHLORIDE issued to AMPHASTAR PHARMS INC

      Submission status for AMPHASTAR PHARMS INC's drug NALOXONE HYDROCHLORIDE (SUPPL-1) with active ingredient NALOXONE HYDROCHLORIDE has changed to 'Approval' on 06/29/2023. Application Category: NDA, Application Number: 208969, Application Classification: Labeling

      6/30/23 9:33:25 AM ET
      $AMPH
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $AMPH
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Director Lee Howard was granted 5,122 shares and covered exercise/tax liability with 923 shares, increasing direct ownership by 3% to 151,976 units (SEC Form 4)

      4 - Amphastar Pharmaceuticals, Inc. (0001297184) (Issuer)

      6/4/25 8:04:41 PM ET
      $AMPH
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Director Deflin Gayle was granted 5,122 shares, increasing direct ownership by 88% to 10,914 units (SEC Form 4)

      4 - Amphastar Pharmaceuticals, Inc. (0001297184) (Issuer)

      6/4/25 7:45:15 PM ET
      $AMPH
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Director Gerst Diane G. was granted 5,122 shares, increasing direct ownership by 27% to 23,756 units (SEC Form 4)

      4 - Amphastar Pharmaceuticals, Inc. (0001297184) (Issuer)

      6/4/25 7:02:01 PM ET
      $AMPH
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $AMPH
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • Amphastar Pharmaceuticals to Present at the 43rd Annual J.P. Morgan Healthcare Conference

      RANCHO CUCAMONGA, CA / ACCESSWIRE / January 8, 2025 / Amphastar Pharmaceuticals, Inc. (NASDAQ:AMPH) announced today that Jack Zhang, CEO and President, and Bill Peters, CFO will be presenting at the 43rd Annual J.P. Morgan Healthcare Conference on Wednesday, January 15th, 2025, at 11:15 am PST. For access, visit Amphastar's Pharmaceuticals website at http://ir.amphastar.com. This webcast will be available for 30 days following the presentation.About Amphastar:Amphastar is a biopharmaceutical company that focuses primarily on developing, manufacturing, marketing, and selling technically-challenging generic and proprietary injectable, inhalation, and intranasal products. Additionally, the Comp

      1/8/25 6:00:00 AM ET
      $AMPH
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Amphastar Pharmaceuticals to Present at the 36th Annual Piper Sandler Healthcare Conference

      RANCHO CUCAMONGA, CA / ACCESSWIRE / November 26, 2024 / Amphastar Pharmaceuticals, Inc. (NASDAQ:AMPH) announced today that Bill Peters, CFO, and Dan Dischner SVP of Corp. Communication, will participate in an Analyst-Moderated fireside chat at the 36th Annual Piper Sandler Healthcare Conference on Wednesday, December 4th, 2024 at 11:30 am EST. For access, visit Amphastar's Pharmaceuticals website at http://ir.amphastar.com. This webcast will be available for 30 days following the presentation.About Amphastar:Amphastar is a biopharmaceutical company that focuses primarily on developing, manufacturing, marketing, and selling technically-challenging generic and proprietary injectable, inhalatio

      11/26/24 4:05:00 PM ET
      $AMPH
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Amphastar Pharmaceuticals to Present at the Jefferies London Healthcare Conference

      RANCHO CUCAMONGA, CA / ACCESSWIRE / November 13, 2024 / Amphastar Pharmaceuticals, Inc. (NASDAQ:AMPH) announced today that Bill Peters, CFO, and Jacob Liawatidewi, EVP of Corporate Administration, will participate in an Analyst-Moderated fireside chat at the Jefferies London Healthcare Conference on Wednesday, November 20, 2024 at 3:30 pm GMT. For access, visit Amphastar's Pharmaceuticals website at http://ir.amphastar.com. This webcast will be available for 30 days following the presentation.About Amphastar:Amphastar is a biopharmaceutical company that focuses primarily on developing, manufacturing, marketing, and selling technically-challenging generic and proprietary injectable, inhalatio

      11/13/24 4:05:00 PM ET
      $AMPH
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $AMPH
    Financials

    Live finance-specific insights

    See more
    • Amphastar Pharmaceuticals to Present at the 43rd Annual J.P. Morgan Healthcare Conference

      RANCHO CUCAMONGA, CA / ACCESSWIRE / January 8, 2025 / Amphastar Pharmaceuticals, Inc. (NASDAQ:AMPH) announced today that Jack Zhang, CEO and President, and Bill Peters, CFO will be presenting at the 43rd Annual J.P. Morgan Healthcare Conference on Wednesday, January 15th, 2025, at 11:15 am PST. For access, visit Amphastar's Pharmaceuticals website at http://ir.amphastar.com. This webcast will be available for 30 days following the presentation.About Amphastar:Amphastar is a biopharmaceutical company that focuses primarily on developing, manufacturing, marketing, and selling technically-challenging generic and proprietary injectable, inhalation, and intranasal products. Additionally, the Comp

      1/8/25 6:00:00 AM ET
      $AMPH
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Amphastar Pharmaceuticals to Present at the 36th Annual Piper Sandler Healthcare Conference

      RANCHO CUCAMONGA, CA / ACCESSWIRE / November 26, 2024 / Amphastar Pharmaceuticals, Inc. (NASDAQ:AMPH) announced today that Bill Peters, CFO, and Dan Dischner SVP of Corp. Communication, will participate in an Analyst-Moderated fireside chat at the 36th Annual Piper Sandler Healthcare Conference on Wednesday, December 4th, 2024 at 11:30 am EST. For access, visit Amphastar's Pharmaceuticals website at http://ir.amphastar.com. This webcast will be available for 30 days following the presentation.About Amphastar:Amphastar is a biopharmaceutical company that focuses primarily on developing, manufacturing, marketing, and selling technically-challenging generic and proprietary injectable, inhalatio

      11/26/24 4:05:00 PM ET
      $AMPH
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Amphastar Pharmaceuticals to Present at the Jefferies London Healthcare Conference

      RANCHO CUCAMONGA, CA / ACCESSWIRE / November 13, 2024 / Amphastar Pharmaceuticals, Inc. (NASDAQ:AMPH) announced today that Bill Peters, CFO, and Jacob Liawatidewi, EVP of Corporate Administration, will participate in an Analyst-Moderated fireside chat at the Jefferies London Healthcare Conference on Wednesday, November 20, 2024 at 3:30 pm GMT. For access, visit Amphastar's Pharmaceuticals website at http://ir.amphastar.com. This webcast will be available for 30 days following the presentation.About Amphastar:Amphastar is a biopharmaceutical company that focuses primarily on developing, manufacturing, marketing, and selling technically-challenging generic and proprietary injectable, inhalatio

      11/13/24 4:05:00 PM ET
      $AMPH
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $AMPH
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • Amphastar Pharmaceuticals downgraded by Analyst with a new price target

      Analyst downgraded Amphastar Pharmaceuticals from Overweight to Neutral and set a new price target of $30.00

      5/12/25 8:19:14 AM ET
      $AMPH
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Amphastar Pharmaceuticals downgraded by Piper Sandler with a new price target

      Piper Sandler downgraded Amphastar Pharmaceuticals from Overweight to Neutral and set a new price target of $36.00 from $66.00 previously

      2/4/25 6:58:07 AM ET
      $AMPH
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Wells Fargo initiated coverage on Amphastar Pharmaceuticals with a new price target

      Wells Fargo initiated coverage of Amphastar Pharmaceuticals with a rating of Equal Weight and set a new price target of $55.00

      11/22/24 7:19:52 AM ET
      $AMPH
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $AMPH
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • SEC Form SC 13G/A filed by Amphastar Pharmaceuticals Inc. (Amendment)

      SC 13G/A - Amphastar Pharmaceuticals, Inc. (0001297184) (Subject)

      3/6/24 10:23:26 AM ET
      $AMPH
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form SC 13G/A filed by Amphastar Pharmaceuticals Inc. (Amendment)

      SC 13G/A - Amphastar Pharmaceuticals, Inc. (0001297184) (Subject)

      2/13/24 4:58:53 PM ET
      $AMPH
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form SC 13G/A filed by Amphastar Pharmaceuticals Inc. (Amendment)

      SC 13G/A - Amphastar Pharmaceuticals, Inc. (0001297184) (Subject)

      2/9/24 5:21:50 PM ET
      $AMPH
      Biotechnology: Pharmaceutical Preparations
      Health Care